{"id":"https://openalex.org/W4363673471","doi":"https://doi.org/10.1016/j.biopsych.2023.02.771","title":"531. GM-1020 is a Novel, Orally Bioavailable NMDA Antagonist With Improved Separation Between Antidepressant and Ataxic Doses Compared to Ketamine","display_name":"531. GM-1020 is a Novel, Orally Bioavailable NMDA Antagonist With Improved Separation Between Antidepressant and Ataxic Doses Compared to Ketamine","publication_year":2023,"publication_date":"2023-04-10","ids":{"openalex":"https://openalex.org/W4363673471","doi":"https://doi.org/10.1016/j.biopsych.2023.02.771"},"language":"en","primary_location":{"id":"doi:10.1016/j.biopsych.2023.02.771","doi":"https://doi.org/10.1016/j.biopsych.2023.02.771","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.biopsych.2023.02.771","pdf_url":null,"source":{"id":"https://openalex.org/S205482884","display_name":"Biological Psychiatry","issn_l":"0006-3223","issn":["0006-3223","1873-2402"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological Psychiatry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Adam Klein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam Klein","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082256940","display_name":"Dino Dvo\u0159\u00e1k","orcid":"https://orcid.org/0000-0003-3884-1393","observed_orcids":["https://orcid.org/0000-0003-3884-1393"]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dino Dvorak","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105990788","display_name":"Eric D. Austin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Austin","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004332028","display_name":"Gerard J. Marek","orcid":"https://orcid.org/0000-0001-8103-4306","observed_orcids":["https://orcid.org/0000-0001-8103-4306"]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gerard Marek","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jonathan Sporn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan Sporn","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024722202","display_name":"Zo\u00eb A. Hughes","orcid":"https://orcid.org/0000-0001-7174-0944","observed_orcids":["https://orcid.org/0000-0001-7174-0944"]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zoe Hughes","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022176441","display_name":"L. L. Kiss","orcid":"https://orcid.org/0000-0002-3234-1374","observed_orcids":["https://orcid.org/0000-0002-3234-1374"]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laszlo Kiss","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077225690","display_name":"Andrew C. Kruegel","orcid":"https://orcid.org/0000-0002-9156-8755","observed_orcids":["https://orcid.org/0000-0002-9156-8755"]},"institutions":[{"id":"https://openalex.org/I4405267702","display_name":"Gilgamesh Pharma (United States)","ror":"https://ror.org/03yv14779","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Kruegel","raw_affiliation_strings":["Gilgamesh Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilgamesh Pharmaceuticals","institution_ids":["https://openalex.org/I4405267702"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405267702"],"apc_list":{"value":4990,"currency":"USD","value_usd":4990},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.05225898,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"93","issue":"9","first_page":"S308","last_page":"S309"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11921","display_name":"Electroconvulsive Therapy Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11337","display_name":"Tryptophan and brain disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2803","display_name":"Biological Psychiatry"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nmda-receptor-antagonist","display_name":"NMDA receptor antagonists","score":0.8199999928474426},{"id":"https://openalex.org/keywords/ketamine","display_name":"ketamine","score":0.8190000057220459},{"id":"https://openalex.org/keywords/treatment-resistant-depression","display_name":"treatment-resistant depression","score":0.7680000066757202},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.7770000100135803},{"id":"https://openalex.org/keywords/ataxia","display_name":"ataxia","score":0.8050000071525574},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.8980000019073486},{"id":"https://openalex.org/keywords/dissociative-disorders","display_name":"dissociative disorders","score":0.3190000057220459}],"concepts":[{"id":"https://openalex.org/C2780795376","wikidata":"https://www.wikidata.org/wiki/Q243547","display_name":"Ketamine","level":2,"score":0.8267726898193359},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.7611316442489624},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.7489646077156067},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.7359784841537476},{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.589924693107605},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.56501305103302},{"id":"https://openalex.org/C2776867660","wikidata":"https://www.wikidata.org/wiki/Q1814941","display_name":"Depression (economics)","level":2,"score":0.43845903873443604},{"id":"https://openalex.org/C2778807096","wikidata":"https://www.wikidata.org/wiki/Q900394","display_name":"Dissociative","level":2,"score":0.43480509519577026},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.41083061695098877},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.39124172925949097},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.19624972343444824},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0628511905670166},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.0},{"id":"https://openalex.org/C139719470","wikidata":"https://www.wikidata.org/wiki/Q39680","display_name":"Macroeconomics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.biopsych.2023.02.771","doi":"https://doi.org/10.1016/j.biopsych.2023.02.771","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.biopsych.2023.02.771","pdf_url":null,"source":{"id":"https://openalex.org/S205482884","display_name":"Biological Psychiatry","issn_l":"0006-3223","issn":["0006-3223","1873-2402"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological Psychiatry","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9391000270843506,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4390589986","https://openalex.org/W4399896931","https://openalex.org/W2589198547","https://openalex.org/W3061798809","https://openalex.org/W2800815779","https://openalex.org/W3128284400","https://openalex.org/W2056041130","https://openalex.org/W4398236811","https://openalex.org/W2950701273","https://openalex.org/W4291335291"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-11T00:00:00"}